Age and Sex Differences in Efficacy of Treatments for Type 2 Diabetes

医学 内科学 2型糖尿病 临床试验 胰高血糖素样肽1受体 糖尿病 二肽基肽酶-4 安慰剂 不利影响 梅德林 内分泌学 受体 兴奋剂 替代医学 法学 病理 政治学
作者
Peter Hanlon,Elaine Butterly,Lili Wei,Heather Wightman,Saleh Ali M. Almazam,Khalid Alsallumi,Jamie Crowther,Ryan McChrystal,Heidi Rennison,Katherine Hughes,Jim Lewsey,Robert S. Lindsay,Stuart J. McGurnaghan,John L. Petrie,Laurie A. Tomlinson,Sarah H. Wild,Amanda Adler,Naveed Sattar,David Phillippo,Sofia Dias
出处
期刊:JAMA [American Medical Association]
被引量:1
标识
DOI:10.1001/jama.2024.27402
摘要

Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and dipeptidyl peptidase 4 (DPP4) inhibitors improve hyperglycemia, and SGLT2 inhibitors and GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACEs) among individuals with type 2 diabetes. It is not clear whether efficacy varies by age or sex. Objective To assess whether age or sex are associated with differences in the efficacy of SGLT2 inhibitors, GLP-1 receptor agonists, and DPP4 inhibitors. Data Sources and Study Selection The MEDLINE and Embase databases and US and Chinese clinical trial registries were searched for articles published from inception to November 2022; in August 2024, the search was updated to capture the trial results. Two reviewers screened for randomized clinical trials of SGLT2 inhibitors, GLP-1 receptor agonists, or DPP4 inhibitors vs a placebo or active comparator in adults with type 2 diabetes. Data Extraction and Synthesis Individual participant data and aggregate data were used to estimate age × treatment interactions and sex × treatment interactions in multilevel network meta-regression models. Main Outcome and Measures Hemoglobin A 1c (HbA 1c ) and MACEs. Results Of the 601 eligible trials identified (592 trials with 309 503 participants reported HbA 1c ; mean age, 58.9 [SD, 10.8] years; 42.3% were female and 23 trials with 168 489 participants reported MACEs; mean age, 64.0 [SD, 8.6] years; 35.3% were female), individual participant data were obtained for 103 trials (103 reported HbA 1c and 6 reported MACEs). The use of SGLT2 inhibitors (vs placebo) was associated with less HbA 1c lowering with increasing age for monotherapy (absolute reduction [AR], 0.24% [95% credible interval {CrI}, 0.10% to 0.38%] per 30-year increment in age), for dual therapy (AR, 0.17% [95% CrI, 0.10% to 0.24%]), and for triple therapy (AR, 0.25% [95% CrI, 0.20% to 0.30%]). The use of GLP-1 receptor agonists was associated with greater HbA 1c lowering with increasing age for monotherapy (AR, −0.18% [95% CrI, −0.31% to −0.05%] per 30-year increment in age) and for dual therapy (AR, −0.24% [95% CrI, −0.40% to −0.07%]), but not for triple therapy (AR, 0.04% [95% CrI, −0.02% to 0.11%]). The use of DPP4 inhibitors was associated with slightly better HbA 1c lowering in older people for dual therapy (AR, −0.09% [95% CrI, −0.15% to −0.03%] per 30-year increment in age), but not for monotherapy (AR, −0.08% [95% CrI, −0.18% to 0.01%]) or triple therapy (AR, −0.01% [95% CrI, −0.06% to 0.05%]). The relative reduction in MACEs with use of SGLT2 inhibitors was greater in older vs younger participants per 30-year increment in age (hazard ratio, 0.76 [95% CrI, 0.62 to 0.93]), and the relative reduction in MACEs with use of GLP-1 receptor agonists was less in older vs younger participants (hazard ratio, 1.47 [95% CrI, 1.07 to 2.02]). There was no consistent evidence for sex × treatment interactions with use of SGLT2 inhibitors and GLP-1 receptor agonists. Conclusions and Relevance The SGLT2 inhibitors and GLP-1 receptor agonists were associated with lower risk of MACEs. Analysis of age × treatment interactions suggested that SGLT2 inhibitors were more cardioprotective in older than in younger people despite smaller reductions in HbA 1c ; GLP-1 receptor agonists were more cardioprotective in younger people.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
David发布了新的文献求助10
刚刚
刚刚
clock完成签到 ,获得积分10
刚刚
风中小懒虫完成签到,获得积分10
1秒前
cindy完成签到 ,获得积分10
2秒前
Tysonqu完成签到,获得积分10
2秒前
科研通AI2S应助Promise采纳,获得10
3秒前
4秒前
淡淡阁完成签到 ,获得积分10
4秒前
念念发布了新的文献求助10
4秒前
漂亮的秋天完成签到 ,获得积分10
6秒前
David完成签到,获得积分10
6秒前
Jason完成签到,获得积分10
6秒前
10秒前
11秒前
11秒前
YY完成签到,获得积分10
12秒前
调皮的凝旋完成签到,获得积分10
13秒前
13秒前
念念完成签到,获得积分20
14秒前
崔悦欣完成签到,获得积分10
16秒前
xiaosui完成签到 ,获得积分10
16秒前
夏初水莲洁完成签到,获得积分10
17秒前
Jasper应助小王采纳,获得10
17秒前
ZXH完成签到,获得积分10
18秒前
18秒前
Promise发布了新的文献求助10
18秒前
个性德天完成签到,获得积分10
19秒前
清颜完成签到 ,获得积分10
20秒前
大侦探皮卡丘完成签到,获得积分10
21秒前
pan完成签到,获得积分10
22秒前
22秒前
白石溪完成签到,获得积分10
24秒前
25秒前
25秒前
坦率的夜玉完成签到,获得积分10
25秒前
KinKrit完成签到 ,获得积分10
25秒前
孤独听雨的猫完成签到 ,获得积分10
26秒前
小谭完成签到 ,获得积分10
27秒前
sl发布了新的文献求助30
27秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
Research on Disturbance Rejection Control Algorithm for Aerial Operation Robots 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038388
求助须知:如何正确求助?哪些是违规求助? 3576106
关于积分的说明 11374447
捐赠科研通 3305798
什么是DOI,文献DOI怎么找? 1819322
邀请新用户注册赠送积分活动 892672
科研通“疑难数据库(出版商)”最低求助积分说明 815029